antibiotics

an Open Access Journal by MDPI

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 7.3

# The Epidemiology of Antimicrobial Resistance in Bloodstream Infections: Focus on Activity of New Antibiotics

Guest Editors:

**Dr. Fabio Arena**
Department of Clinical and Experimental Medicine, University of Foggia, Via Luigi Pinto, 71122 Foggia, Italy

**Dr. Gianfranco La Bella**
1. Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Foggia, Italy
2. Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy

Deadline for manuscript submissions:
**30 September 2024**

## Message from the Guest Editors

The spread of multidrug-resistant (MDR) organisms, particularly among Gram-negative (G-neg) bacteria, is a matter of serious concern. Invasive infections (particularly bloodstream infections, BSIs) sustained by MDR organisms are correlated with significant patient morbidity and mortality worldwide.

The excess mortality associated with BSIs is mainly attributed to the limited availability of active drugs.

Several new antibiotics with activity against MDR G-neg bacteria have been released in recent years. These drugs have fundamentally changed the therapeutic approach for invasive MDR G-neg bacterial infections.

Monitoring the in vitro activity of these new antibiotics over time is of fundamental importance for the identification of antimicrobial management and antimicrobial resistance containment strategies.

This Special Issue seeks to publish manuscripts that could expand knowledge on the epidemiology of antimicrobial resistance in BSI, particularly regarding the activity of new drugs against MDR G-neg bacteria. Studies aimed at investigating the epidemiology, microbiology and risk factors associated with mortality from MDR bacterial bloodstream infections are welcome.

mdpi.com/si/148610

Special Issue

antibiotics

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 7.3

an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Nicholas Dixon**
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

## Contact Us

*Antibiotics* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi